Payment overview · 2025
General Payments
$135.77
2 reported records · 2 companies
Healthcare provider profile · identity verified
Tammy Vanderstelt
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · KALAMAZOO, MI · NPI 1588775365
Verified facts
What the public records show
CMS Open Payments records show Tammy Vanderstelt received $135.77 in general payments during 2025 across 2 reported records.
Neurocrine BioSciences, Inc. accounted for 83.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Rexulti.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $113.43 | 83.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.34 | 16.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $135.77 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $113.43 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 472 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 53 |
| Sertraline Hcl | Sertraline Hcl | 340 | 60 |
| Donepezil Hcl | Donepezil Hcl | 326 | 51 |
| Eliquis | Apixaban | 318 | 40 |
| Trazodone Hcl | Trazodone Hcl | 306 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 64 |
| Memantine Hcl | Memantine Hcl | 262 | 37 |
| Potassium Chloride | Potassium Chloride | 253 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 46 |
| Mirtazapine | Mirtazapine | 242 | 54 |
| Gabapentin | Gabapentin | 239 | 44 |
| Warfarin Sodium | Warfarin Sodium | 217 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 30 |
| Buspirone Hcl | Buspirone Hcl | 189 | 39 |
| Torsemide | Torsemide | 187 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 165 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 164 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 35 |
| Furosemide | Furosemide | 161 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 150 | 23 |
| Lisinopril | Lisinopril | 150 | 27 |
| Losartan Potassium | Losartan Potassium | 150 | 39 |
| Carvedilol | Carvedilol | 149 | 26 |
| Divalproex Sodium | Divalproex Sodium | 144 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 128 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 118 | 23 |
| Clonazepam | Clonazepam | 112 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 108 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 21 |
| Alprazolam | Alprazolam | 101 | 13 |
| Levetiracetam | Levetiracetam | 98 | 16 |
| Lorazepam | Lorazepam | 96 | 20 |
| Linzess | Linaclotide | 95 | 17 |
| Tramadol Hcl | Tramadol Hcl | 83 | 29 |
| Prednisone | Prednisone | 80 | 40 |
| Metformin Hcl | Metformin Hcl | 78 | 20 |
| Enulose | Lactulose | 72 | 15 |
| Omeprazole | Omeprazole | 72 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 30 |
| Simvastatin | Simvastatin | 72 | 15 |
| Risperidone | Risperidone | 71 | suppressed |
| Fentanyl | Fentanyl | 70 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | suppressed |
| Clonidine | Clonidine | 67 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 12 |
| Olanzapine | Olanzapine | 64 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | suppressed |
| Bumetanide | Bumetanide | 63 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 63 | 15 |
| Spironolactone | Spironolactone | 62 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 60 | 12 |
| Midodrine Hcl | Midodrine Hcl | 60 | 17 |
| Baclofen | Baclofen | 56 | 13 |
| Meloxicam | Meloxicam | 56 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 55 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 11 |
| Pregabalin | Pregabalin | 53 | 13 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 24 |
| Finasteride | Finasteride | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 25 |
| Allopurinol | Allopurinol | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Primidone | Primidone | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 16 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | 14 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 14 |
| Latanoprost | Latanoprost | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 35 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 35 | suppressed |
| Cephalexin | Cephalexin | 33 | 27 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 32 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Ingrezza | Valbenazine Tosylate | 30 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 30 | 11 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 27 | 13 |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Xtampza Er | Oxycodone Myristate | 25 | suppressed |
| Clozapine | Clozapine | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Famotidine | Famotidine | 24 | 11 |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Protonix | Pantoprazole Sodium | 22 | suppressed |
| Hydroxyurea | Hydroxyurea | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 17 |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Risperidone Er | Risperidone Microspheres | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $135.77 · 2 records | Neurocrine BioSciences, Inc. | INGREZZA, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Neurocrine BioSciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error